Summary of Conference Call Notes Industry Overview - The industry is transitioning from information technology to a trillion-level AI application era, shifting evaluation standards from hardware deployment to actual application effectiveness [2][3] - The procurement model is evolving from low-cost, single-point purchases to full lifecycle strategic partnerships [2][3] - AI technology is activating diverse funding sources within universities, expanding market size 4-5 times compared to traditional information technology [2][4] Company Insights - The company has developed a proprietary large model, "Damingbai," with a recall rate exceeding 98% and retrieval time under 2 seconds, outperforming general models [2][5] - The product matrix covers courses, majors, and university levels, with 500 projects delivered by the end of 2025 and nearly 1,000 contracts signed [2][5] - The business model features high lifetime value (LTV) and high repurchase rates, with top clients generating over 10 million annually [2][5] - Gross margin for AI intelligent body business reached 80% in Q1 2026, with a steady net profit margin expected around 20% [2][5] Market Dynamics - Universities prioritize application effectiveness, high professional barriers, and rational "quality-price ratio" procurement logic when selecting technology partners [3][4] - The competitive landscape is fragmented, favoring partners that provide sustainable services rather than experimental technology purchases [3][4] Technological and Competitive Advantages - The company has established core competencies in technology R&D, customer trust, and data assets, including a vast repository of teaching data and algorithms [5][6] - The proprietary model "Damingbai" is specifically designed for higher education, demonstrating superior accuracy and reliability compared to general models [6][7] - The company plays a national role in AI application, directly interfacing with regulatory bodies and participating in the formulation of data security and quality standards [7][8] Product Matrix and Commercialization - The product matrix includes infrastructure tools, business layers, management layers, and strategic layers, with a focus on course-level and professional-level products [9][10] - A key growth point for 2026 is the course-level intelligent body, which has already delivered significant results in late 2025 [9][10] - The intelligent body product is a lightweight tool that allows for direct sales, facilitating rapid project signings [15][16] Financial Performance - The company has achieved continuous high-speed growth, with a 70% year-on-year increase in its core knowledge graph business, which has reached a cumulative revenue of 10 billion [20][21] - The gross margin for the AI intelligent body business is at a historical high, reflecting successful product optimization [20][21] - The company’s customer base includes top-tier universities, with a reach of over 1,500 schools annually, relying on brand influence for revenue growth [21][22] Future Growth and Strategy - R&D investment in 2025 was 20% of revenue, expected to decrease to 15-20% in 2026 as revenue growth outpaces R&D spending [22][24] - The company plans to enhance customer value and average revenue per user (ARPU) through horizontal and vertical expansion of application scenarios [25][26] - The knowledge graph business is expected to see strong growth driven by diverse funding sources and increasing demand for AI integration in educational settings [22][23]

Core Viewpoint - The article emphasizes the importance of intangible cultural heritage (ICH) as a vital part of local history and culture, highlighting the need for digital transformation to address challenges in its transmission and preservation [1] Group 1: Digital Transformation of ICH - The construction of a digital knowledge graph is crucial for the systematic protection of regional ICH, integrating both explicit and implicit cultural elements to create a dynamic preservation model [2][3] - The launch of the "Henan ICH Map" exemplifies the integration of ICH resources through digital technology, mapping various cultural dimensions such as geographical distribution and talent lineage [3] Group 2: Multi-modal Experience and Immersive Transmission - The inherent non-material nature of ICH necessitates innovative transmission methods that incorporate multi-sensory experiences, breaking traditional barriers and enhancing engagement [4] - Technologies like VR, AR, and MR are being utilized to create immersive experiences, allowing users to interact with ICH in a virtual environment, thus addressing the challenges of traditional transmission methods [5] Group 3: Media Integration and Enhanced Communication - The rise of new media platforms has transformed the way ICH is communicated, with platforms like Douyin and Xiaohongshu significantly increasing the visibility and engagement of ICH content [6][7] - The integration of traditional and new media enhances the effectiveness of ICH dissemination, allowing for targeted and interactive storytelling that resonates with audiences [7] Group 4: Challenges of Digitalization - The reliance on algorithms in ICH transmission raises concerns about the potential loss of individual style and regional characteristics, leading to homogenization of cultural expressions [8][9] - There is a need to establish mechanisms for protecting local cultural genes while navigating the challenges posed by digital technologies, ensuring that the essence of ICH is preserved [9]

Summary of the Conference Call on Hualan's AI Pharmaceutical Developments Company and Industry Overview - **Company**: Hualan Co., Ltd. (华兰股份) - **Industry**: AI Pharmaceutical Development - **Context**: The conference call was organized by Tianfeng Securities and several other brokerages to discuss Hualan's recent developments in the AI pharmaceutical sector, particularly its collaboration with various experts and companies in the field [1][2]. Key Points and Arguments Hualan's Background and Business Model - Hualan has over 30 years of experience and was listed in 2021, primarily known for its medical rubber products [3]. - The company has a stable revenue and profit stream, with a strong customer base of over 1,000 pharmaceutical companies, many of which have long-term relationships spanning 20-30 years [4]. - Hualan has completed capacity construction for new products and has a solid cash flow, which supports its entry into AI pharmaceuticals [5]. AI Pharmaceutical Strategy - Hualan's strategy involves leveraging its extensive customer base to support AI pharmaceutical initiatives, aiming to reduce time and costs for technology teams to connect with clients [6]. - The company plans to open its customer resource pool to all teams joining Hualan, enhancing collaboration and trust with clients [6]. Internal and External Development - Hualan has established an expert committee to guide its AI pharmaceutical direction, focusing on internal incubation and external investments [9][10]. - The company is developing four main areas: knowledge graph, small molecules, antibodies, and small nucleic acids, with a focus on mature and validated technologies [10]. Collaboration with Kema Bio - Hualan has invested in Kema Bio, which focuses on antibody design and optimization, emphasizing the importance of data accumulation and model optimization for effective drug development [12][13]. - Kema Bio's approach is to optimize models for specific targets, such as GPCRs, and to enhance the specificity and efficacy of antibodies [13][16]. Knowledge Graph Development - Hualan's knowledge graph initiative aims to structure and visualize relationships between various biological entities, enhancing drug repurposing and safety monitoring [19][20]. - The knowledge graph will facilitate the identification of new indications for existing drugs, potentially shortening development timelines [22][23]. Future Goals and Market Positioning - Hualan aims to position its AI pharmaceutical business on par with its core rubber product business, with a goal to exceed current performance levels within 3-5 years [43][44]. - The company is focused on integrating AI capabilities with existing operations to enhance service offerings and customer engagement [44]. Additional Important Content - The conference highlighted the importance of collaboration with top-tier experts and the establishment of a robust technological foundation for future developments [9][10]. - Hualan's commitment to maintaining high standards in its AI pharmaceutical initiatives was emphasized, with specific performance milestones set for the knowledge graph team [46]. - The call also addressed the competitive landscape and the need for high-quality knowledge graphs to gain market acceptance [33][34]. This summary encapsulates the key discussions and strategic directions outlined during the conference call, reflecting Hualan's ambitions in the AI pharmaceutical sector and its operational synergies.

Core Viewpoint - Hualan Co., Ltd. (301093.SZ) announced a collaboration between its wholly-owned subsidiary Hainan Lingqing Smart Pharmaceutical Technology Co., Ltd. and a technical team led by former CTO of Insilico Medicine, Yu Kaixian, and Academician Liu Jun from the American Academy of Sciences [1] Group 1 - The collaboration involves the establishment of a joint venture company, with Hualan's subsidiary holding a controlling stake [1] - The joint venture will focus on drug repurposing and pharmacovigilance services centered around knowledge graphs, integrating heterogeneous data sources to provide intelligent solutions for drug development and safety management [1] - The specific business scope of the joint venture will be determined based on industrial registration information [1]

Group 1 - The core point of the article is that Hualan Co., Ltd. announced the establishment of a joint venture with Insilicom LLC's former CTO and a team led by Academician Liu Jun, focusing on drug repurposing and pharmacovigilance services using knowledge graphs and artificial intelligence technology [1] - Hualan's wholly-owned subsidiary, Hainan Lingqing Intelligent Pharmaceutical Technology Co., Ltd., will invest 6 million yuan and hold a 60% stake in the joint venture [1] - The joint venture aims to explore applications of artificial intelligence in pharmaceutical research and drug safety management [1]

Group 1 - China People's Insurance Group (China P&C) is committed to enhancing service efficiency through technological innovation, focusing on the development of an intelligent Q&A system for medical insurance knowledge to meet the growing demand for medical insurance inquiries [1][2] - The project aims to build a high-efficiency and precise medical insurance knowledge intelligent Q&A system, with a tender announcement published on January 4, 2026, attracting several well-known technology companies to participate [1] - The procurement focuses on system development and knowledge base construction, utilizing intelligent Q&A technology to help China P&C quickly respond to medical insurance policy inquiries, reduce labor costs, and improve user experience [1] Group 2 - Cloud Wisdom Technology Co., Ltd. (Cloud Wisdom) successfully won the bid for the medical insurance knowledge intelligent Q&A system project from China P&C, with a bid amount of 2.714 million yuan [2] - This collaboration marks a significant breakthrough for Cloud Wisdom in the application of artificial intelligence within the insurance industry, providing core support for the intelligentization of medical insurance services at China P&C [2] - Cloud Wisdom's strong capabilities in natural language processing and knowledge graph technology were recognized by evaluation experts, leading to its top position in the list of winning candidates [1][2]

Core Viewpoint - The company, Haizhi Technology Group, is set to launch an IPO from February 5 to February 10, 2026, offering 28.03 million H-shares globally, with a maximum price of HKD 28.0 per share, and aims to raise approximately HKD 648 million for various strategic initiatives [1][6]. Group 1: Company Overview - Haizhi Technology Group is a leading enterprise in China focused on developing Atlas graph solutions and industrial-grade AI solutions through graph-model fusion technology [2]. - The company's core product, the Atlas graph solution, leverages its advanced graph computing and data analysis capabilities, enabling efficient integration and management of data from multiple sources [2][4]. Group 2: Market Position and Performance - According to Frost & Sullivan, the company ranks fifth among industrial-grade AI providers in China by revenue, holding a market share of 2.8%, and is the leading provider of AI solutions centered around graphs with a market share of approximately 50% [3]. - The company's revenue grew from RMB 313 million in 2022 to RMB 503 million in 2024, representing a compound annual growth rate (CAGR) of 26.8% [3]. Group 3: Technological Advancements - The company is recognized as the first in the industry to effectively reduce hallucination in large models through knowledge graphs, ensuring high reliability in output accuracy [3]. - The Atlas intelligent agent, launched in September 2023, enhances the reasoning capabilities of large language models in specific industry contexts [4]. Group 4: Strategic Focus and Investment - The company emphasizes parallel development of the Atlas graph solution and Atlas intelligent agent, allowing it to capture growth opportunities during digital transformation [5]. - The proceeds from the IPO will be allocated as follows: approximately 45% for R&D to enhance graph-model fusion technology, 20% for optimizing the Atlas intelligent agent, and 15% for deepening customer collaboration and exploring new application scenarios [6].

Core Viewpoint - The company, Haizhi Technology Group, is set to launch an IPO from February 5 to February 10, 2026, offering 28.03 million H-shares globally, with a maximum price of HKD 28.0 per share, aiming to raise approximately HKD 648 million for various strategic initiatives [1][6]. Group 1: Company Overview - The company is a leading enterprise in China focused on developing Atlas graph solutions and industrial-grade AI solutions through graph-model fusion technology [2]. - The Atlas graph solution is one of the core products, enabling efficient integration, processing, and management of data from multiple sources [2]. Group 2: Market Position and Performance - According to Frost & Sullivan, the company ranks fifth among industrial-grade AI providers in China with a market share of 2.8%, and first among graph-centric AI providers with a market share of approximately 50% [3]. - The company's revenue grew from RMB 313 million in 2022 to RMB 503 million in 2024, representing a compound annual growth rate (CAGR) of 26.8% [3]. Group 3: Technological Advancements - The company has developed a breakthrough technology that effectively reduces the "hallucination" phenomenon in large language models, ensuring high reliability in output facts and low rates of unverifiable errors [3]. - The Atlas intelligent agent, launched in September 2023, enhances the reasoning capabilities of large language models in specific industry contexts [4]. Group 4: Strategic Focus and Investment - The company is focusing on parallel development of the Atlas graph solution and Atlas intelligent agent, which allows it to capture growth opportunities during different stages of digital transformation [5]. - The company has entered cornerstone investment agreements with several investors, agreeing to raise approximately USD 15 million under certain conditions [6]. Group 5: Use of Proceeds - The net proceeds from the global offering are planned to be allocated as follows: approximately 45% for R&D to enhance graph-model fusion technology, 20% for optimizing the Atlas intelligent agent, 15% for deepening customer collaboration, 10% for strategic investments, and 10% for working capital and general corporate purposes [6].

Group 1 - The company plans to globally offer 28.03 million H-shares, with 2.8032 million shares available in Hong Kong and 25.227 million shares for international offering, with the offering period from February 5 to February 10, 2026, and expected pricing on February 11, 2026 [1] - The expected share price range is HKD 25.6 to HKD 28.0, with a trading unit of 200 shares, and the shares are anticipated to start trading on the Hong Kong Stock Exchange on February 13, 2026 [1] - The company is a leading enterprise in China, focusing on developing Atlas graph solutions and industrial-grade AI solutions through graph-model fusion technology [2] Group 2 - The company has entered into cornerstone investment agreements, with cornerstone investors agreeing to subscribe for shares at the offering price, totaling approximately USD 15 million, with 4.3492 million shares to be subscribed based on a median offering price of HKD 26.80 [3] - The expected net proceeds from the global offering are approximately HKD 648.4 million, assuming a share price of HKD 26.80 [4] - The proceeds will be allocated as follows: approximately 45% for R&D to enhance graph-model fusion technology, 20% for optimizing Atlas intelligent agents, 15% for deepening customer collaboration and exploring new application scenarios, 10% for strategic investments, mergers, and acquisitions, and 10% for working capital and general corporate purposes [4]

北京海致科技集團股份有限公司 Beijing Haizhi Technology Group Co., Ltd. （於中華人民共和國註冊成立的股份有限公司） 股份代號 : 2706 全球發售 聯席保薦人、整體協調人、聯席全球協調人、 聯席賬簿管理人及聯席牽頭經辦人 重要提示 重要提示：閣下如對本招股章程的任何內容有任何疑問，應徵詢獨立專業意見。 Beijing Haizhi Technology Group Co., Ltd. 北京海致科技集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 全球發售 全球發售項下的發售股份數目 ： 28,030,200股H股 香港發售股份數目 ： 2,803,200股H股（可予重新分配） 國際發售股份數目 ： 25,227,000股H股（可予重新分配） 最高發售價 ： 每股H股28.0港元，另加1.0%的經紀 佣金，0.0027%證監會交易徵費、 0.00565%香港聯交所交易費 及0.00015%會財局交易徵費（須於申 請時以港元繳足，多繳款項可予退還） 面值 ： 每股H股人民幣0.1元 股份代號 ： 2706 聯席保薦人、整體協調人、聯席全球協調人、 聯席賬簿管 ...